DX-88/ecallantide is a kallikrein antibody peptide fragment that is FDA approved to treat hereditary angioedema (HAE), a condition in which bradykinin production is deregulated due to a mutation in the C1 inhibitor gene, leading to potentially fatal edema [118]. Here, KLK4 is linked to hereditary angioedema.